ADMA BIOLOGICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $4.29 per share for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2020-11-05
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2020-03-31 was $4.60, a 3.16% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2019-03-31 was $4.75, a 77.24% increase year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $2.68, a 70.22% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $9.00.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2019 was $4.60, a 45.11% decline from fiscal 2018.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2018 was $8.38, a 7.10% decline from fiscal 2017.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2017 was $9.02, a 14.47% increase from fiscal 2016.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2016 was $7.88.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2020-09-30 | $4.29 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $4.34 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $4.60 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $4.60 10-K · filed 2020-03-13 | |||
| 2019-09-30 | $4.88 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $5.54 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $4.75 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $8.38 10-K · filed 2020-03-13 | |||
| 2018-09-30 | $8.03 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $2.68 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | $2.68 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | $9.02 10-K · filed 2019-03-13 | |||
| 2017-09-30 | $8.60 10-Q · filed 2017-11-03 | |||
| 2017-06-30 | $8.92 10-Q · filed 2017-08-11 | |||
| 2017-03-31 | $9.00 10-Q · filed 2017-05-12 | |||
| 2016-12-31 | $7.88 10-K · filed 2018-03-29 | |||
| 2016-09-30 | $7.88 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |